87 results about "Multi resistant bacteria" patented technology

The invention discloses a full D-type antibacterial peptide with high enzymolysis stability and broad-spectrum antibacterial activity and application thereof. The antibacterial peptide is obtained by sequentially and repeatedly arranging D-type tryptophan, D-type arginine and D-type lysine for four times and carrying out C-terminal amidation; the amino acid sequence of the gene is (D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-NH2, and is marked as DWRK-12. The antibacterial peptide shows broad-spectrum antibacterial activity and excellent stability, can effectively resist clinically separated multidrug resistant strains, and keeps high cell selectivity at the same time. Due to the characteristics, the antibacterial peptide has important application value in the aspect of developing novel antibacterial drugs, especially in the field of treatment of infection of multiple drug-resistant bacteria.

The invention relates to application of ten antibacterial peptides in the antimicrobial field. The ten antibacterial peptides have strong antibacterial activity on multi-drug-resistant bacteria, including but not limited to gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae and the like, and gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis and the like. Activity research proves that any one of the ten antibacterial peptides has a remarkable effect of inhibiting, killing or preventing microbial infection. Due to the strong antibacterial property of any antibacterial peptide, the antibacterial peptide has wide application potential in the aspects of preparing antibacterial drugs, preservatives, antibacterial coatings, antibacterial fibers, antibacterial packaging materials and the like. Due to the unique property of the antibacterial peptide in the aspect of antibacterial performance, a new direction is provided for the development of efficient and reliable antibacterial agents and antibacterial technologies and products in multiple fields.

The invention discloses a preparation method of recombinant collagen nano-composite hydrogel for repairing wounds infected by multiple drug-resistant bacteria, which comprises the following steps: binding copper porphyrin pi-pi on titanium carbide nanosheets to form MXene coated CuTCPP nanoparticles, and carrying out amidation reaction on 3-aminophenylboronic acid and recombinant collagen to obtain the recombinant collagen nano-composite hydrogel for repairing wounds infected by multiple drug-resistant bacteria. MXene coated CuTCPP is doped into a modified recombinant collagen system and mixed with a polyvinyl alcohol solution, and the recombinant collagen nano-composite hydrogel is prepared. The self-healing property endowed by the dynamic cross-linking characteristic of the phenylboronic acid ester bond in the composite hydrogel disclosed by the invention can be highly adapted to irregular wounds; the nano particles with the heterojunction structure can be combined with photothermal therapy and photodynamic therapy to efficiently sterilize wounds; the hydrogel has the antibacterial property and the property of promoting wound healing, and can comprehensively and efficiently treat wounds infected by multiple drug-resistant bacteria.

The invention discloses a mussel byssus polypeptide with antibacterial performance and application thereof.The mussel byssus polypeptide has an obvious inhibiting effect on gram-positive bacteria and gram-negative bacteria, can inhibit formation of biological membranes of the gram-positive bacteria and the gram-negative bacteria, shows different antibacterial activities on multiple drug-resistant bacteria, and has the advantages that the mussel byssus polypeptide can be used for preparing a drug-resistant agent; and the hydrogel has low cytotoxicity and good biocompatibility, and shows good adhesion capability. The polypeptide is short in peptide chain and small in molecular weight, is a micromolecular polypeptide with great value, shows wide application potential in multiple fields, and has important value in the fields of medicine preparation, medical equipment and daily chemical products.

The invention relates to a Cu2-xSe-Pt nano material, a microneedle patch, a preparation method and application. The Cu < 2-x > Se (at) Pt nano material is composed of a Cu < 2-x > Se nanosphere and platinum modified on the surface of the Cu < 2-x > Se nanosphere in situ. The invention provides a preparation method of a Cu2-xSe-Pt nano-material, which comprises the following steps: adding PSS, SeO2 and AA into water, heating and stirring, adding copper salt and AA, reacting, and adding water and a hexachloroplatinic acid solution to obtain the Cu2-xSe-Pt nano-material. The invention provides an application of a Cu < 2-x > Se (at) Pt nano material. The invention also provides a microneedle patch as well as a preparation method and application thereof. The invention provides a novel material for resisting multi-drug-resistant bacteria, which solves the problems that the existing single antibacterial strategy is limited and the expected curative effect cannot be achieved, also solves the problem of cytotoxicity of the existing nano enzyme, realizes deep drug delivery, ensures efficient local drug release and avoids systemic toxicity.

The invention discloses a preparation method of nano ozone water and application of the nano ozone water in killing food-borne pathogenic bacteria, and belongs to the technical field of bactericides. The nano ozone water is prepared by utilizing the ultra-fine bubble generator and the ozone generator, and the prepared nano ozone water is high in stability, not easy to decompose and high in practicability. The nano ozone water can achieve an effective killing effect on escherichia coli, salmonella, enterococcus, campylobacter and clinical multi-drug-resistant bacteria thereof, and a new resource is provided for preparing a safe and reliable antibacterial product.

The invention discloses a multi-drug-resistant bacterium infection risk assessment method, system and device and a storage medium, and belongs to the technical field of medical data analysis, and the method comprises the steps: collecting a clinical related data set of an ICU patient, and carrying out the preprocessing of the clinical related data set to obtain a to-be-assessed data set; performing feature extraction on the to-be-evaluated data set in combination with a long short-term memory network and a time sequence attention mechanism to obtain a high-risk feature set; inputting the high-risk feature set into a pre-constructed dynamic scoring model, and calculating a corresponding risk score through the dynamic scoring model; and grading the risk score based on a preset grading rule to obtain a current risk level, and outputting a corresponding intervention strategy through a preset intervention decision mechanism based on the current risk level. According to the scheme, the high-risk feature set is extracted by combining the long-short-term memory network with the time sequence attention mechanism, then the risk score is calculated through the dynamic scoring model, the risk level is determined according to the preset grading rule, the intervention strategy is output, and the accuracy of MDRO infection assessment is improved.

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

The invention relates to a heavy metal-antibiotic multiple resistant bacteria and its application, which belongs to the field of microbial remediation technology. The heavy metal-antibiotic multiple resistant bacteria described in this paper is Rossellomorea oryzaecorticis ZC255, which is preserved at China General Microbiological Culture Collection Center on Jun. 12, 2023, the biological preservation number is CGMCC No. 27617. This strain not only has high activity, simple culture method and strong adaptability, but also can survive in solid medium with high concentration of heavy metals and antibiotics. It also has excellent metal tolerance; it can effectively degrade a variety of antibiotics and can be applied to the remediation of heavy metal-contaminated or antibiotic-contaminated or heavy metal and antibiotic-contaminated water or soil. In addition, it has the advantages of large adsorption capacity, low cost, high efficiency, good effect and no secondary pollution.

The invention discloses a photoresponse-essential oil synergistic antibacterial polymer and an application thereof in resisting multiple drug-resistant bacteria. Citronellol (CT) is subjected to an esterification reaction to prepare a CMA monomer, the CMA monomer and a glycidyl methacrylate (GMA) monomer are copolymerized to prepare a polymer PG9C2, and then TBO is introduced to obtain the antibacterial polymer PG9C2T1. The improvement of the antibacterial activity of the TBO is derived from the improvement of the fat solubility of the TBO, the enhancement of the interaction between the TBO and bacterial cells, the improvement of the accumulation of the TBO in the cells, the penetration of the TBO through cell membranes and the play of roles in the cells, the improvement of the utilization efficiency of ROS, and the sterilization by improving the water solubility of the essential oil through the mechanism of destroying bacterial membranes. According to the invention, high-efficiency and low-toxicity drug-resistant bacteria based on natural products are synthesized, the limitation of a single antibacterial mode is broken through, and technical support is provided for developing a novel low-drug-resistance antibacterial therapy.

A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.

The invention discloses application of black phosphorus loaded cerium dioxide composite temperature-sensitive hydrogel in preparation of diabetes wound anti-inflammatory drugs, and relates to the technical field of hydrogel preparation. The black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel is used for diabetes wound anti-inflammation, and the preparation method of the black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel specifically comprises the following steps that a composite material of black phosphorus nanosheets loaded cerium dioxide nanoparticles is used for preparing the black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel, and the black phosphorus-loaded cerium dioxide composite temperature-sensitive hydrogel is used for diabetes wound anti-inflammation. The composite hydrogel with the temperature-sensitive characteristic is jointly prepared from the hydrogel and pluronic F127. The invention further provides application of the black phosphorus loaded cerium dioxide composite temperature-sensitive hydrogel in preparation of diabetes wound anti-inflammatory drugs, antibacterial drugs, antioxidant drugs and arthritis treatment drugs, and the problems that chronic infected wounds are not healed for a long time and multiple drug-resistant bacteria are formed due to abuse of antibiotics are effectively solved.

The invention belongs to the technical field of biomedical materials. The invention provides a composite nano preparation for treating diabetic ulcer and promoting wound healing and a preparation method thereof. The preparation method comprises the following steps: mixing tetra (4-carboxyl phenyl) porphyrin and FeCl3. 6H2O for reaction, then adding a mixed solution composed of benzoic acid and 3, 5-dicarboxyphenylboronic acid for reaction, and then performing centrifugal drying; dispersing in water, adding a chloroplatinic acid solution, stirring, adding a sodium borohydride solution, continuously stirring, and centrifugally drying; stirring with a mixture of curcumin, flavonoid glycoside and astragaloside in ethanol, and carrying out centrifugal drying; and finally, stirring with glucose oxidase in water, and centrifugally drying. The composite nano preparation provided by the invention has an excellent antibacterial effect on multi-drug-resistant bacteria, can effectively destroy a biological membrane, can well treat diabetic ulcer and promote wound healing, and has a relatively good application prospect.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

The present invention belongs to the medical field, and relates to novel β-lactamase inhibitors, for the treatment of bacterial infections in combination with β-lactam antibiotics, including infection caused by drug resistant organisms and especially multi-drug resistant organisms. The present invention includes compounds according to formula (I): or pharmaceutically acceptable salts thereof, wherein M and R are as defined herein.

This invention relates to the field of bacterial infection treatment technology, and discloses an enzyme-responsive probe, its preparation method, and its applications. The probe of this invention constructs an enzyme-responsive "prodrug" structure by introducing cephalosporin derivative linker units that can be specifically cleaved by β-lactamases onto a hemicyanine optical framework. This structure remains optically and therapeutically inert in normal tissues, but is selectively activated at the site of infection by drug-resistant bacteria. When the probe contacts multidrug-resistant bacteria that overexpress β-lactamases, the linker units undergo enzymatic cleavage, releasing hemicyanine active molecules with near-infrared fluorescence emission and highly efficient photothermal conversion capabilities, achieving high-contrast fluorescence imaging and controllable photothermal sterilization of the infection focus. The probe of this invention has a simple synthetic route, mild conditions, and reliable purification methods, making it suitable for large-scale preparation, especially for the precise diagnosis and targeted photothermal synergistic treatment of superficial tissue infections such as bacterial keratitis.

The invention relates to a Nile red derivative with photodynamic-photothermal performance as well as preparation and application thereof, two Nile red derivatives (TPACN and TPAOMCN) are elaborately designed and synthesized, and the structural formula is as follows: # imgabs0. The Nile red derivative disclosed by the invention can generate a large amount of active oxygen and efficient photothermal conversion under the irradiation of 660nm laser; a strong photodynamic-photothermal treatment effect is shown, multi-drug-resistant bacterium infection can be resisted to promote wound repair, and propagation of monkey pox viruses can be blocked. The TPAOMCN NFs provided by the invention can effectively remove drug-resistant bacteria in mouse wounds under laser irradiation, regulate inflammatory response and promote healing of infected wounds. In simulation of characteristic impetigo of monkey pox, after TPAOMCN NFs and laser treatment, virus titer in lesion is significantly reduced, infected lesion tissue is rapidly repaired, transmission of viruses to healthy mice is effectively blocked, and the TPAOMCN NFs has a huge application prospect.

The present invention discloses a mussel foot thread polypeptide with antibacterial properties and its application. This mussel foot thread polypeptide has obvious inhibitory effects on both Gram-positive bacteria and Gram-negative bacteria, can inhibit the formation of their biofilms, and at the same time shows different antibacterial activities against multi-drug resistant bacteria. It has low cytotoxicity and good biocompatibility, and exhibits good adhesion ability. Its peptide chain is short and its molecular weight is small. It is a small molecule polypeptide with great value and shows broad application potential in multiple fields, and has important value in the fields of drug preparation, medical devices and daily chemical products.

The invention relates to an engineered bacteriophage targeting drug-resistant gram-negative bacteria, a screening method and application. The engineered phage is Escherichia phage M13, the preservation time is February 11, 2025, the preservation address is China Center for Type Culture Collection (CCTCC), Wuhan University, Wuchang District, Wuhan City, Hubei Province, and the preservation number is CCTCC No: M 2025196. The invention also provides application of the engineered bacteriophage in preparation of medicines for treating and diagnosing multi-drug-resistant gram-negative bacterium infection. The invention also provides a kit for diagnosing or treating multi-drug-resistant gram-negative bacterium infection, and the kit comprises the bacteriophage. The invention also provides a screening method of the engineered bacteriophage. The invention solves the problem that the natural bacteriophage is targeted to single species of bacteria and is difficult to cope with common mixed infection of multiple drug-resistant bacteria clinically.

Composition comprising an antibacterial benzimidazole-pyrazole hybrid compound, N-(1H-Benzo[d]imidazol-2-yl)-1-(3-(4-Fluorphenyl)-1-phenyl-1H-pyrazole-4-yl)methanimin (AJ01), characterized at a minimum inhibitory concentration of 12.5 µg / ml against Staphylococcus aureus, including multi-resistant strains, and with predicted high affinity for bacterial target proteins.

The invention relates to the technical field of natural product extraction and purification and biological medicine, in particular to day lily polysaccharide with broad-spectrum antibacterial activity and application of the day lily polysaccharide. The molecular weight of the hemerocallis citrina polysaccharide is 1959 Da, monosaccharide components of the hemerocallis citrina polysaccharide mainly comprise fructose (88.87%) and glucose (11.13%), and the hemerocallis citrina polysaccharide is high-fructose neutral polysaccharide. The main chain is-> 1)-beta-D-Fruf-(2->), side chains are connected to O-6 sites of partial main chain residues, and the side chains comprise beta-D-Fruf-(2->) and-> 6)-beta-D-Fruf-(2->); the molar percentages of the sugar residues Fruf1, 2, Fruf2, Fruf1, 2, 6, Fruf2, 6 and Glc1, 6 are respectively 41.94%, 23.59%, 9.27%, 16.80% and 8.40%, and the molar percentages of the sugar residues Fruf1, 2, Fruf2, Fruf2, Fruf6 and Glc1, 6 are respectively 41.94%, 23.59%, 9.27%, 16.80% and 8.40%; the hemerocallis citrina baroni polysaccharide shows remarkable bacteriostatic activity on clinically separated multi-drug-resistant strains and standard strains, and shows dose dependence; in addition, the improvement effect of the hemerocallis citrina polysaccharide on the lung tissue injury is enhanced along with the increase of the dosage, the effect can be quantified and repeatable, and the requirements of drug development are met.

The invention discloses an aromatic polyketone compound as well as a preparation method and application thereof. The compound GaB (3) has an effect of treating infection of multiple drug-resistant bacteria. The compound is obtained by being separated from a secondary metabolite of the symbiotic Streptomyces sp.QHH-9511 of licheniformis, and the compound 2, the compound 3, the compound 4 and the compound 5 are new compounds. According to the present invention, the research results show that the GaB can effectively sterilize a variety of drug-resistant bacteria (methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, carbapenem-resistant acinetobacter baumannii, multi-drug-resistant pseudomonas aeruginosa, multi-drug-resistant salmonella, and the like); in addition, the compound has the characteristics of broad-spectrum sterilization, biofilm formation inhibition and low-frequency drug resistance, and can be combined with other antibiotics to cope with super bacteria. Mechanism research shows that GaB is combined with glucosamine-6-phosphate synthetase (GlmS) to prevent synthesis of cell walls so as to play an antibacterial role, and a plurality of constructed living body models show that the compound can effectively reduce the content of bacteria in a body and promote wound repair and has in-vivo medication safety. The research result shows that the GaB can be used as a safe and effective novel pilot natural active small molecule for resisting infection of multiple drug-resistant bacteria.

The invention discloses an external antibacterial medicine composition as well as a preparation method and application thereof, and belongs to the technical field of antibacterial medicines. The external antibacterial pharmaceutical composition provided by the invention comprises a medicinal active component and a pharmaceutically acceptable carrier, wherein the medicinal active component comprises polymyxin B sulfate, trimethoprim sulfate and lidocaine; every 10 g of the antibacterial pharmaceutical composition for external use is prepared from the following components in parts by weight: 40000 to 60000 U of polymyxin B sulfate, 0.08 to 0.16 g of trimethoprim sulfate and 0.30 to 0.35 g of lidocaine. The pharmaceutical composition disclosed by the invention has broad-spectrum inhibition on multiple drug-resistant bacteria such as common gram-negative drug-resistant bacteria and acinetobacter baumannii on a wound surface, synchronously plays a synergistic role in relieving inflammatory response of the wound surface and relieving local pain, and remarkably improves the medication safety and the comprehensive treatment effect while ensuring excellent antibacterial activity.

The invention relates to the technical field of microorganisms, in particular to lactobacillus reuteri with antibiotic post-effect prevention and control and Chinese herbal medicine synergistic interaction functions, the lactobacillus reuteri is named as HBNK11 and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC M20251479. The lactobacillus reuteri provided by the invention has a remarkable inhibition effect on gram-positive bacteria and gram-negative bacteria, and breaks through the limitation of narrow antibacterial spectrum of traditional probiotics. Meanwhile, the survival rate in simulated gastric juice with the pH value of 2.5 reaches 112.4%, it is ensured that the strain stably survives and plays a role in the strong acid environment of the gastrointestinal tract of livestock and poultry, and the problem that the gastrointestinal tract tolerance of traditional probiotics is poor is solved. When the lactobacillus reuteri is coordinated with a Chinese herbal medicine monomer, the monomer dosage can be reduced by 128 times. The lactobacillus reuteri provides a high-quality resource for developing a novel microbial feed additive, and has important application value for reducing antibiotic dependence in a breeding link and preventing and controlling propagation of multiple drug-resistant bacteria.

This disclosure relates to the crystalline hydrate forms of (S)-2-((R)-6-(N-((1s,3S)-3-amino-cyclobutyl)carbamimidoyl)chroman-2-yl)-2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((S)-2,2-dimethyl-4-oxo-1-(sulfooxy)azetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)propanoic acid, including crystalline hydrate form A, crystalline hydrate form B and crystalline hydrate form D, which are useful as antibiotic agents for the treatment of bacterial infections, such as bacterial infections caused by gram-negative bacteria, including strains that are multidrug resistant.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

The invention described herein generally relates to novel therapeutic compounds, and in particular to carbonic anhydrase inhibitors as a narrow spectrum antibiotics against drug resistant bacteria and methods for treating those infection diseases in mammals using the described carbonic anhydrase inhibitors or a pharmaceutical formulation thereof.

The utility model discloses a multi-drug-resistant bacterium protective article storage device, which relates to the technical field of medical instruments and comprises a protective bag, the top and the bottom of the protective bag are both of an opening structure, a protective bag opening component is arranged at the opening of the top of the protective bag, and a protective article taking component is arranged at the opening of the bottom of the protective bag. The interior of the protection bag is divided into a plurality of interlayers, and the multiple interlayers are arranged in an up-down communicating mode. A multi-layer structure is arranged in the protective bag, so that different protective articles can be conveniently classified and stored; the top opening of the protective bag is fixedly provided with a suspension support frame, and the bottom opening is fixedly provided with a protective article taking assembly, so that protective articles can be conveniently supplemented into the protective bag and taken from the bottom opening of the protective bag in time; the protective article is simple in structure and reasonable in design, and can effectively solve the problems that the existing protective articles with multiple drug-resistant bacteria are placed dispersedly, are inconvenient to take and are easy to cause cross infection when in use.

This invention relates to the field of microbial technology, and more particularly to a broad-spectrum Aeromonas hydrophila phage and its applications. The Aeromonas hydrophila phage AhP2505006 is classified as follows: Aeromonas hydrophila Phage AhP2505006, with accession number CCTCC NO: M20251307, exhibits cross-species lytic activity. It can effectively lyse *Aeromonas*, *Vibrio parahaemolyticus* and *Vibrio alginolyticus*, and *Citrobacter freundii*. It also possesses excellent targeting ability against multidrug-resistant strains and broad host spectrum characteristics, achieving a lysis rate of up to 80% against multidrug-resistant *Aeromonas hydrophila*. In the prevention and control of diseases caused by various pathogens, or in practical scenarios facing the limitations of traditional antibiotics and highly specific bacteriophages, it has become a highly promising solution.